Hims & Hers Health, Inc. (HIMS)
NYSE:HIMS
Want to see HIMS full AI Analyst Report?
HIMS Stock Chart & Stats
$25.05
-$0.61(-2.20%)
At close: 4:00 PM EST
$25.05
-$0.61(-2.20%)
Day’s Range― - ―
52-Week Range$13.74 - $70.43
Previous CloseN/A
Volume4.28M
Average Volume (3M)31.58M
Market Cap
$5.41B
Enterprise Value$6.12B
Total Cash (Recent Filing)$750.88M
Total Debt (Recent Filing)$1.13B
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Aug 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding219,561,140
10 Day Avg. Volume28,227,132
30 Day Avg. Volume31,578,709
Financial Highlights & Ratios
PEG Ratio-33.00
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue2.58
Enterprise Value/Gross Profit3.82
Enterprise Value/Ebitda61.34
Forecast
1Y Price Target
$28.51Price Target Upside13.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$2.89B
Bulls Say, Bears Say
Bulls Say
Branded Product And Member EconomicsLaunch of a branded weight‑loss subscription bundled with clinical support and eligibility for health savings accounts strengthens the value proposition and supports the potential for higher pricing and improved contribution per subscriber.
Partnership And Litigation RemovalThe agreement with Novo Nordisk and dismissal of its lawsuit removes a major litigation overhang, materially lowering legal and enforcement risk and smoothing the path for branded product distribution on the platform.
Regulatory OptionalityA procedural FDA re‑review of several wellness peptides creates optionality for future product approvals and the potential to repurpose existing GLP‑1 manufacturing capacity toward new peptide offerings, opening additional revenue pathways.
Bears Say
Regulatory Clearance UncertaintyThe FDA procedural notice does not authorize commercial marketing, so meaningful revenue from peptides remains contingent on future regulatory clearances and agency decisions.
Regulatory Enforcement And Visibility RiskHeightened regulatory scrutiny, tightening guidance on compounding, and referrals to law enforcement increase reputational and legal risk and lower visibility for adjusted earnings.
Revenue Recognition And Margin PressureTransitioning from compounded to branded medications and shifting to recording only the company’s share of transactions is likely to reduce reported revenue and could create near‑term margin headwinds as compounded sales are wound down.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health, Inc.’s price range in the past 12 months?
Hims & Hers Health, Inc. lowest stock price was $13.74 and its highest was $70.43 in the past 12 months.
What is Hims & Hers Health, Inc.’s market cap?
Hims & Hers Health, Inc.’s market cap is $5.41B.
When is Hims & Hers Health, Inc.’s upcoming earnings report date?
Hims & Hers Health, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 78 days.
How were Hims & Hers Health, Inc.’s earnings last quarter?
Hims & Hers Health, Inc. released its earnings results on May 11, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of $0.025 by -$0.425.
Is Hims & Hers Health, Inc. overvalued?
According to Wall Street analysts Hims & Hers Health, Inc.’s price is currently Undervalued.
Does Hims & Hers Health, Inc. pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
What is Hims & Hers Health, Inc.’s EPS estimate?
Hims & Hers Health, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Hims & Hers Health, Inc. have?
Hims & Hers Health, Inc. has 219,561,140 shares outstanding.
What happened to Hims & Hers Health, Inc.’s price movement after its last earnings report?
Hims & Hers Health, Inc. reported an EPS of -$0.4 in its last earnings report, missing expectations of $0.025. Following the earnings report the stock price went up 3.077%.
Which hedge fund is a major shareholder of Hims & Hers Health, Inc.?
Currently, no hedge funds are holding shares in HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.51 (13.82% Upside)
$28.51 (13.82% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 59%
Bearish news 59%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.62%
12-Months-Change
Fundamentals
Return on Equity
-2.48%
Trailing 12-Months
Asset Growth
154.24%
Trailing 12-Months
Company Description
Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
HIMS Company Deck
HIMS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of near-term headwinds tied to a deliberate strategic pivot (one-time restructuring charges, gross-margin pressure, GAAP loss and short-term volatility) alongside several strong growth signals: raised full-year revenue guide, rapid adoption of branded GLP-1 products (125k+ Wegovy shipments in six weeks and on track for >100k monthly subscribers), international revenue growth (~10x to $78M), positive operating cash flow ($89M) and deep investments in AI, labs and verticalized supply chain. Management expects accelerating EBITDA in H2 as monthly cohorts compound and efficiencies emerge. Given the substantial operational and commercial progress and the forward-looking guidance offsetting temporary accounting and margin noise, the positive operational momentum and upgraded outlook outweigh the short-term financial disruptions.View all HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$28.51
▲(13.82% Upside)
Technical Analysis
Ownership Overview
5.13% Insiders
18.78% Mutual Funds
12.93% Other Institutional Investors
43.21% Public Companies and Individual Investors